Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI)

Martin Rowland, Alessandro Cavecchi, Frank Thielmann, Janusz Kulon, Jag Shur, Robert Price

Research output: Contribution to journalArticle

Abstract

PURPOSE: To measure the charge to mass (Q/M) ratios of the impactor stage masses (ISM) from commercial Flixotide™ 250 μg Evohaler, containing fluticasone propionate (FP), Serevent™ 25 μg Evohaler, containing salmeterol xinafoate (SX), and a combination Seretide™ 250/25 μg (FP/SX) Evohaler metered dose inhalers (MDIs). Measurements were performed with a purpose built bipolar charge measurement apparatus (bp-NGI) based on an electrostatic precipitator, which was directly connected below Stage 2 of a Next Generation Impactor (NGI). METHODS: Five successive shots of the respective MDIs were actuated through the bp-NGI. The whole ISM doses were electrostatically precipitated to determine their negative, positive and net Q/m ratios. RESULTS: The ISM doses collected in the bp-NGI were shown to be equivalent to those collected in a standard NGI. FP particles, actuated from Flixotide™ and Seretide™ MDIs, exhibited greater quantities of negatively charged particles than positive. However, the Q/m ratios of the positively charged particles were greater in magnitude. SX particles from Serevent™ exhibited a greater quantity of positively charged particles whereas SX aerosol particles from Seretide™ exhibited a greater quantity of negatively charged particles. The Q/m ratio of the negatively charged SX particles in Serevent™ was greater in magnitude than the positively charged particles. CONCLUSIONS: The bp-NGI was used to quantify the bipolar Q/m ratios of aerosol particles collected from the ISMs of commercial MDI products. The positive charge recorded for each of the three MDIs may have been enhanced by the presence of charged ice crystals formed from the propellant during the aerosolisation process.

LanguageEnglish
Article number15
Number of pages1
JournalPharmaceutical Research
Volume36
Issue number1
Early online date26 Nov 2018
DOIs
StatusPublished - 1 Jan 2019

Keywords

  • Administration, Inhalation
  • Aerosols/chemistry
  • Chemistry, Pharmaceutical/instrumentation
  • Equipment Design
  • Fluticasone/chemistry
  • Fluticasone-Salmeterol Drug Combination/chemistry
  • Metered Dose Inhalers
  • Particle Size
  • Powders/chemistry
  • Salmeterol Xinafoate/chemistry
  • Static Electricity
  • Surface Properties
  • Suspensions/chemistry
  • Technology, Pharmaceutical/instrumentation

Cite this

Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI). / Rowland, Martin; Cavecchi, Alessandro; Thielmann, Frank; Kulon, Janusz; Shur, Jag; Price, Robert.

In: Pharmaceutical Research, Vol. 36, No. 1, 15, 01.01.2019.

Research output: Contribution to journalArticle

@article{6880668598654500884ca5847a1dabe0,
title = "Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI)",
abstract = "PURPOSE: To measure the charge to mass (Q/M) ratios of the impactor stage masses (ISM) from commercial Flixotide™ 250 μg Evohaler, containing fluticasone propionate (FP), Serevent™ 25 μg Evohaler, containing salmeterol xinafoate (SX), and a combination Seretide™ 250/25 μg (FP/SX) Evohaler metered dose inhalers (MDIs). Measurements were performed with a purpose built bipolar charge measurement apparatus (bp-NGI) based on an electrostatic precipitator, which was directly connected below Stage 2 of a Next Generation Impactor (NGI). METHODS: Five successive shots of the respective MDIs were actuated through the bp-NGI. The whole ISM doses were electrostatically precipitated to determine their negative, positive and net Q/m ratios. RESULTS: The ISM doses collected in the bp-NGI were shown to be equivalent to those collected in a standard NGI. FP particles, actuated from Flixotide™ and Seretide™ MDIs, exhibited greater quantities of negatively charged particles than positive. However, the Q/m ratios of the positively charged particles were greater in magnitude. SX particles from Serevent™ exhibited a greater quantity of positively charged particles whereas SX aerosol particles from Seretide™ exhibited a greater quantity of negatively charged particles. The Q/m ratio of the negatively charged SX particles in Serevent™ was greater in magnitude than the positively charged particles. CONCLUSIONS: The bp-NGI was used to quantify the bipolar Q/m ratios of aerosol particles collected from the ISMs of commercial MDI products. The positive charge recorded for each of the three MDIs may have been enhanced by the presence of charged ice crystals formed from the propellant during the aerosolisation process.",
keywords = "Administration, Inhalation, Aerosols/chemistry, Chemistry, Pharmaceutical/instrumentation, Equipment Design, Fluticasone/chemistry, Fluticasone-Salmeterol Drug Combination/chemistry, Metered Dose Inhalers, Particle Size, Powders/chemistry, Salmeterol Xinafoate/chemistry, Static Electricity, Surface Properties, Suspensions/chemistry, Technology, Pharmaceutical/instrumentation",
author = "Martin Rowland and Alessandro Cavecchi and Frank Thielmann and Janusz Kulon and Jag Shur and Robert Price",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11095-018-2544-9",
language = "English",
volume = "36",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI)

AU - Rowland, Martin

AU - Cavecchi, Alessandro

AU - Thielmann, Frank

AU - Kulon, Janusz

AU - Shur, Jag

AU - Price, Robert

PY - 2019/1/1

Y1 - 2019/1/1

N2 - PURPOSE: To measure the charge to mass (Q/M) ratios of the impactor stage masses (ISM) from commercial Flixotide™ 250 μg Evohaler, containing fluticasone propionate (FP), Serevent™ 25 μg Evohaler, containing salmeterol xinafoate (SX), and a combination Seretide™ 250/25 μg (FP/SX) Evohaler metered dose inhalers (MDIs). Measurements were performed with a purpose built bipolar charge measurement apparatus (bp-NGI) based on an electrostatic precipitator, which was directly connected below Stage 2 of a Next Generation Impactor (NGI). METHODS: Five successive shots of the respective MDIs were actuated through the bp-NGI. The whole ISM doses were electrostatically precipitated to determine their negative, positive and net Q/m ratios. RESULTS: The ISM doses collected in the bp-NGI were shown to be equivalent to those collected in a standard NGI. FP particles, actuated from Flixotide™ and Seretide™ MDIs, exhibited greater quantities of negatively charged particles than positive. However, the Q/m ratios of the positively charged particles were greater in magnitude. SX particles from Serevent™ exhibited a greater quantity of positively charged particles whereas SX aerosol particles from Seretide™ exhibited a greater quantity of negatively charged particles. The Q/m ratio of the negatively charged SX particles in Serevent™ was greater in magnitude than the positively charged particles. CONCLUSIONS: The bp-NGI was used to quantify the bipolar Q/m ratios of aerosol particles collected from the ISMs of commercial MDI products. The positive charge recorded for each of the three MDIs may have been enhanced by the presence of charged ice crystals formed from the propellant during the aerosolisation process.

AB - PURPOSE: To measure the charge to mass (Q/M) ratios of the impactor stage masses (ISM) from commercial Flixotide™ 250 μg Evohaler, containing fluticasone propionate (FP), Serevent™ 25 μg Evohaler, containing salmeterol xinafoate (SX), and a combination Seretide™ 250/25 μg (FP/SX) Evohaler metered dose inhalers (MDIs). Measurements were performed with a purpose built bipolar charge measurement apparatus (bp-NGI) based on an electrostatic precipitator, which was directly connected below Stage 2 of a Next Generation Impactor (NGI). METHODS: Five successive shots of the respective MDIs were actuated through the bp-NGI. The whole ISM doses were electrostatically precipitated to determine their negative, positive and net Q/m ratios. RESULTS: The ISM doses collected in the bp-NGI were shown to be equivalent to those collected in a standard NGI. FP particles, actuated from Flixotide™ and Seretide™ MDIs, exhibited greater quantities of negatively charged particles than positive. However, the Q/m ratios of the positively charged particles were greater in magnitude. SX particles from Serevent™ exhibited a greater quantity of positively charged particles whereas SX aerosol particles from Seretide™ exhibited a greater quantity of negatively charged particles. The Q/m ratio of the negatively charged SX particles in Serevent™ was greater in magnitude than the positively charged particles. CONCLUSIONS: The bp-NGI was used to quantify the bipolar Q/m ratios of aerosol particles collected from the ISMs of commercial MDI products. The positive charge recorded for each of the three MDIs may have been enhanced by the presence of charged ice crystals formed from the propellant during the aerosolisation process.

KW - Administration, Inhalation

KW - Aerosols/chemistry

KW - Chemistry, Pharmaceutical/instrumentation

KW - Equipment Design

KW - Fluticasone/chemistry

KW - Fluticasone-Salmeterol Drug Combination/chemistry

KW - Metered Dose Inhalers

KW - Particle Size

KW - Powders/chemistry

KW - Salmeterol Xinafoate/chemistry

KW - Static Electricity

KW - Surface Properties

KW - Suspensions/chemistry

KW - Technology, Pharmaceutical/instrumentation

UR - http://www.scopus.com/inward/record.url?scp=85057153561&partnerID=8YFLogxK

U2 - 10.1007/s11095-018-2544-9

DO - 10.1007/s11095-018-2544-9

M3 - Article

VL - 36

JO - Pharmaceutical Research

T2 - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 1

M1 - 15

ER -